Yihe Daida to Hepacivirus
This is a "connection" page, showing publications Yihe Daida has written about Hepacivirus.
Connection Strength
0.508
-
Hepatitis B Virus Infection and Hepatitis C Virus Treatment in a Large Cohort of Hepatitis C-Infected Patients in the United States. Gastroenterology. 2018 02; 154(3):754-758.
Score: 0.150
-
Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis?C and Cirrhosis. Adv Ther. 2024 Feb; 41(2):744-758.
Score: 0.057
-
The Persistence of Underreporting of Hepatitis C as an Underlying or Contributing Cause of Death, 2011-2017. Clin Infect Dis. 2021 09 07; 73(5):891-894.
Score: 0.048
-
Low Uptake of Direct-acting Antiviral Therapy Among Hepatitis C Patients With Advanced Liver Disease and Access to Care, 2014-2017. J Clin Gastroenterol. 2021 01; 55(1):77-83.
Score: 0.046
-
Psychosocial Obstacles to Hepatitis C Treatment Initiation Among Patients in Care: A Hitch in the Cascade of Cure. Hepatol Commun. 2021 03; 5(3):400-411.
Score: 0.046
-
Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure. J Viral Hepat. 2019 10; 26(10):1210-1217.
Score: 0.042
-
Sustained virological response does not improve long-term glycaemic control in patients with type 2 diabetes and chronic hepatitis C. Liver Int. 2019 06; 39(6):1027-1032.
Score: 0.040
-
Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes. Aliment Pharmacol Ther. 2019 03; 49(5):599-608.
Score: 0.040
-
Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings. Infect Dis Clin North Am. 2018 06; 32(2):253-268.
Score: 0.039